共 331 条
[1]
Pitt B(1999)The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 709-717
[2]
Zannad F(2011)Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 11-21
[3]
Remme WJ(2003)Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 1309-1321
[4]
Cody R(2014)Spironolactone for heart failure with preserved ejection fraction N Engl J Med 370 1383-1392
[5]
Castaigne A(2017)2017 comprehensive update of the Canadian cardiovascular society guidelines for the management of heart failure Can J Cardiol 33 1342-1433
[6]
Perez A(2004)Gynecomastia and antihypertensive therapy J Clin Hypertens 6 469-470
[7]
Palensky J(2010)Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(1)(c) levels in patients with chronic heart failure Am Heart J 160 915-921
[8]
Wittes J(2008)Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles Diabetologia 51 762-768
[9]
Zannad F(2004)Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes Diabetologia 47 1687-1694
[10]
McMurray JJ(2006)The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy Metab Clin Exp 55 1645-1652